Global Healthcare and Pharma Market Outlook

Features

Revealed: drug development companies best positioned to weather future industry disruption

Our analysis reveals that companies from USA are some of the best-prepared players in the drug development game.

Data Journalism Team

Analyst Comment

Can AI-generated prognostic forecasts substitute patients in oncology trials?

Analyst Comment

Drop in smoking among US adults with psychiatric disorders

Analyst Comment

Syphilis continues to rise in US despite Covid-19 pandemic restrictions

News

Clinical trial data company Beaconcure eyes US expansion

News

Tested solutions to solve new challenges: breaking silos key in future proofing clinical trial supply chains

Filings

Future of Work: Cipla tops list of filing mentions

Patents

Future of Work: Takeda, Bayer among top innovators in Q4

Analyst Comment

Burden of brain cancer will continue to rise in the US ageing population

GlobalData Healthcare

Features

The future of medtech goes beyond Microsoft’s AI creep

Features

2022 forecast: decentralised trials to reach new heights with 28% jump

Kezia Parkins and Andrew Hillman

Features

Future of work hiring in clinical trial operations industry rose in November

Analyst Comment

Delta Variant in US Children May Place Millions of Adults in Nursing Homes at Risk

GlobalData Healthcare

Features

The Metaverse: Future of post-pandemic business, or just another attempt to kickstart VR/AR adoption?

News

Lysogene begins dosing in Phase I/II GM1 gangliosidosis trial in US

Divya Tirumalaraju

Features

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir

Features

China’s tech future depends on children and surveillance

Features

Covid-19 mRNA vaccine booster outlook positive despite heart inflammation risk

Reynald Castañeda

News

FAU team develops new method to forecast Covid-19 trial outcome

Divya Tirumalaraju

News

Inotrem to extend Covid-19 therapy trial to France and Belgium

Features

Technology and the Future of Work: A lot more than just Zoom calls

Comment

Covid-19 vaccine purchasing in EU likely to pivot to traditional reimbursement models from 2023

Reynald Castañeda

News

Transgene and BioInvent get US approval to trial oncolytic virus

Divya Tirumalaraju

Analyst Comment

Comirnaty for teens will bring US closer to herd immunity and increase Pfizer’s market share

GlobalData Healthcare

Comment

Covid-19 hospitalisation spike in the US a clear trigger for future mRNA vaccine booster deployment but several arguments for earlier distribution

Reynald Castañeda

News

Isofol concludes Japanese enrolment in Phase III cancer drug study

Analyst Comment

Alzheimer’s disease prevalence variation between Spain, the US and Japan

GlobalData Healthcare

Comment

Revised Covid-19 vaccine prices likely by the fall in the US but premium pricing possibility debatable

Reynald Castañeda

News

Fujifilm starts anti-influenza drug trial in Japan to treat Covid-19

Comment

LoA Update: Outlook Therapeutics’ Phase III drug sees a 7 and 10-point LoA jump in two eye disease indications after positive safety data

Comment

LoA Update: Amryt’s Juxtapid sees 7-point surge in US approval prospects in familial chylomicronaemia due to positive investigator-led Phase III trial

Reynald Castañeda

Comment

Outlook Therapeutics’ bevacizumab-vikg for wet AMD has experts anticipating Phase III success, but biased design likely to limit uptake

Comment

LoA Update: ReGenTree’s US approval chance for timbetasin in dry eye drops six points after Phase III miss

Analyst Comment

Chemotherapy trends in hematological versus solid tumours vary across the US and 5EU as other drug classes gain positioning

GlobalData Healthcare

Comment

LoA Update: Scynexis’ ibrexafungerp sees 3-point increase in US approval potential with positive interim Phase III systemic candidiasis data

Reynald Castañeda

Features

OCT West Coast: the post-pandemic outlook for clinical trials

News

Takeda doses first subject in Japanese Covid-19 vaccine trial

Comment

Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase Ib

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close